Allergan Aesthetics announced new global consumer research highlighting how patient expectations in medical aesthetics are evolving, and will present the next evolution of its AA Signature? framework, to address this changing treatment need, at the AMWC 2026 in Monaco. The findings are based on one of the largest global consumer studies exploring attitudes toward aesthetic treatments, surveying more than 12,000 beauty-involved consumers across nine countries.1 The research provides new insight into how patients are navigating an expanding range of aesthetic options and the growing role practitioners play in guiding treatment decisions.

At AMWC 2026, Allergan Aesthetics will launch the research findings in a new report Layered Beauty: The New Aesthetic Mindset. The report highlights that 62% find multiple aesthetic treatments appealing1, 59% are likely to adopt a structured multi-treatment approach1 and 78% would feel more satisfied with their aesthetic journey working to an agreed long-term plan with their practitioner. AA Signature?: One Year On: AA Signature?

was developed in collaboration with experts as a portfolio-led framework to support personalised, multimodal treatment planning. One year on, AA Signature? is evolving to include new elevated looks, expanded indications and enhanced product integration, reflecting changing patient expectations.

Allergan Aesthetics' new research found that 74% intend to improve facial skin quality in the next 12 months,1 while 63% cite improving elasticity and addressing ageing as top aesthetic goals1(p33). Around 30% identify skin quality improvement as the starting point for a multi-treatment plan. Introducing AA Signature?

Skin360+: Designed around the way the skin behaves across layers and dimensions, AA Signature? Skin 360+ was driven by real-world consumer needs and reinforces Allergan Aesthetics' commitment to continuously evolve how its portfolio works alone, and in combination with other modalities. At AMWC 2026 Allergan Aesthetics and globally recognised faculty will provide structured guidance to support sequential treatment planning, integrating injectable treatments with energy-based devices.

AMI Programme at AMWC 2026: Allergan Aesthetics will bring the research insights and AA Signature? evolution to life through two flagship symposia delivered by the Allergan Medical Institute (AMI). Day One 26 March at 10:45- 12:45: AA Signature: Personalized Multimodal Skin Journeys for the Modern Aesthetic Patient.

This session will focus on AA Signature? Skin360 using Juvéderm, BOTOX? and HArmonyCa?, alongside energy-based device integration within multimodal treatment strategies with world renowned experts Dr. Reha Yavuzer, Dr. Julia Carroll, Dr. Andre Braz, Dr. Raafat Lakis and Dr. Sheila Mulatti.

Day Two 27 March at 09:45 ? 12:45: AA Signature? and MD Codes?: Innovation Driving the Future of Medical Aesthetics: This symposium will explore AA Signature?

distinct definition and lower face refinement using structured, anatomy-led sequencing with contributions from Dr Mauricio De Maio, Dr. Alessandro Gritti and Dr Gu. Live injection sessions from Dr Mauricio De Maio will demonstrate combination approaches for chin and jawline correction alongside skin quality improvement, reinforcing the principle of small changes delivering meaningful impact.